Regeneron director sells shares under 10b5-1 plan

Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock on February 9, 2026 in a series of small open-market trades.

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock on February 9, 2026 in a series of small open-market trades. Reported sale prices ranged from about $775.63 to $787.82 per share.

The filing states these transactions were made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025, which pre-schedules trades. Following the transactions, Ryan directly beneficially owned 17,803 shares of Regeneron common stock.

Insider Trade Summary

Net Seller: 100 shares

Net Sell 13 txns

Insider RYAN ARTHUR F

Role Director

Sold 100 shs ($78K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1	$775.63	$775.63
Sale	Common Stock	10	$776.59	$8K
Sale	Common Stock	57	$777.56	$44K
Sale	Common Stock	12	$778.53	$9K
Sale	Common Stock	5	$779.41	$4K
Sale	Common Stock	1	$780.09	$780.09
Sale	Common Stock	5	$781.48	$4K
Sale	Common Stock	1	$782.53	$782.53
Sale	Common Stock	3	$783.34	$2K
Sale	Common Stock	1	$784.59	$784.59
Sale	Common Stock	1	$785.71	$785.71
Sale	Common Stock	2	$786.29	$2K
Sale	Common Stock	1	$787.82	$787.82

Holdings After Transaction: Common Stock — 17,803 shares (Direct)

Footnotes (7)

1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
2. F2. Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
3. F3. Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
4. F4. Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
5. F5. Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
6. F6. Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
7. F7. Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Regeneron (REGN) disclose for Arthur F. Ryan?

Regeneron disclosed that director Arthur F. Ryan sold 100 shares of common stock on February 9, 2026, through multiple open-market trades. The transactions were reported on a Form 4 insider filing with prices in the mid-$770s to high-$780s per share.

At what prices did Arthur F. Ryan sell Regeneron (REGN) shares?

Arthur F. Ryan’s reported sales occurred at prices ranging from about $775.63 to $787.82 per Regeneron share. Several trades used volume-weighted average prices based on executions within narrower intraday price ranges disclosed in the footnotes.

How many Regeneron (REGN) shares does Arthur F. Ryan own after this Form 4?

After the reported February 9, 2026 transactions, Arthur F. Ryan directly beneficially owned 17,803 shares of Regeneron common stock. This post-transaction holding figure is explicitly stated in the Form 4’s non-derivative securities table.

Was the Regeneron (REGN) insider sale by Arthur F. Ryan under a Rule 10b5-1 plan?

Yes. The filing explains that the disposition was made under a trading plan intended to comply with Rule 10b5-1(c), adopted on October 31, 2025. Such pre-arranged plans schedule trades in advance to help manage insider trading concerns.

What role does Arthur F. Ryan hold at Regeneron (REGN)?

Arthur F. Ryan is identified as a director of Regeneron Pharmaceuticals, Inc. on the Form 4. The relationship section of the filing has the “Director” box checked, while officer and 10% owner boxes are not selected.

What type of security did Arthur F. Ryan trade in this Regeneron (REGN) filing?

All reported transactions involve Regeneron common stock as a non-derivative security. The Form 4’s Table I lists multiple small open-market sales of common stock, and the derivative securities table shows no derivative positions acquired or disposed of in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RYAN ARTHUR F

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		S(1)		1	D	$775.63	17,902	D
Common Stock	02/09/2026		S(1)		10	D	$776.59(2)	17,892	D
Common Stock	02/09/2026		S(1)		57	D	$777.56(3)	17,835	D
Common Stock	02/09/2026		S(1)		12	D	$778.53(4)	17,823	D
Common Stock	02/09/2026		S(1)		5	D	$779.41(5)	17,818	D
Common Stock	02/09/2026		S(1)		1	D	$780.09	17,817	D
Common Stock	02/09/2026		S(1)		5	D	$781.48(6)	17,812	D
Common Stock	02/09/2026		S(1)		1	D	$782.53	17,811	D
Common Stock	02/09/2026		S(1)		3	D	$783.34(7)	17,808	D
Common Stock	02/09/2026		S(1)		1	D	$784.59	17,807	D
Common Stock	02/09/2026		S(1)		1	D	$785.71	17,806	D
Common Stock	02/09/2026		S(1)		2	D	$786.29	17,804	D
Common Stock	02/09/2026		S(1)		1	D	$787.82	17,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.

2. Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

7. Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

	/s/ Arthur F. Ryan	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.